Leap Therapeutics, Inc. financial data

Symbol
LPTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
47 Thorndike Street, Suite B1 1, Cambridge, MA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Dekkun Corp (to 1/7/2011)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 581 % -24.5%
Debt-to-equity 20.4 % +7.1%
Return On Equity -98 % +28.3%
Return On Assets -81.4 % +12.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.3M shares +49.7%
Common Stock, Shares, Outstanding 38.3M shares +49.7%
Entity Public Float 77.7M USD -17.2%
Common Stock, Value, Issued 38K USD +46.2%
Weighted Average Number of Shares Outstanding, Basic 39.1M shares +166%
Weighted Average Number of Shares Outstanding, Diluted 39.1M shares +166%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 52.4M USD -28.4%
General and Administrative Expense 13.4M USD -0.59%
Operating Income (Loss) -65.7M USD +24.1%
Net Income (Loss) Attributable to Parent -60.1M USD +27.1%
Earnings Per Share, Basic -0.86 USD/shares +88.3%
Earnings Per Share, Diluted -0.86 USD/shares +88.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 78.5M USD -14.2%
Assets, Current 79.6M USD -15.2%
Deferred Income Tax Assets, Net 142K USD -16%
Property, Plant and Equipment, Net 5K USD -75%
Operating Lease, Right-of-Use Asset 475K USD +1.71%
Other Assets, Noncurrent 15K USD -80%
Assets 81.4M USD -15.1%
Accounts Payable, Current 7.81M USD +20.1%
Employee-related Liabilities, Current 2.37M USD +45.1%
Accrued Liabilities, Current 7.35M USD +52.2%
Liabilities, Current 15.6M USD +32.6%
Operating Lease, Liability, Noncurrent 39K USD +2.63%
Liabilities 15.6M USD +32.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3K USD -99.3%
Retained Earnings (Accumulated Deficit) -434M USD -16.2%
Stockholders' Equity Attributable to Parent 65.8M USD -21.7%
Liabilities and Equity 81.4M USD -15.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -15.5M USD -22.2%
Net Cash Provided by (Used in) Financing Activities -210K USD -102%
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 38.3M shares +49.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -15.7M USD -143%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 78.5M USD -14.2%
Deferred Tax Assets, Valuation Allowance 38.2M USD -52.8%
Deferred Tax Assets, Gross 38.2M USD -52.8%
Operating Lease, Liability 482K USD +1.69%
Depreciation 5K USD +25%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -60.5M USD +26.3%
Lessee, Operating Lease, Liability, to be Paid 506K USD +2.43%
Property, Plant and Equipment, Gross 226K USD 0%
Operating Lease, Liability, Current 443K USD +1.61%
Lessee, Operating Lease, Liability, to be Paid, Year Two 268K USD -40.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 273K USD +20.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 24K USD +20%
Lessee, Operating Lease, Liability, to be Paid, Year Three 268K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 500M USD +9.29%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 54K USD +31.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares